These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849 [TBL] [Abstract][Full Text] [Related]
4. Fibroid growth and medical options for treatment. Chabbert-Buffet N; Esber N; Bouchard P Fertil Steril; 2014 Sep; 102(3):630-9. PubMed ID: 25171950 [TBL] [Abstract][Full Text] [Related]
5. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas. Milewska G; Ponikwicka-Tyszko D; Bernaczyk P; Lupu O; Szamatowicz M; Sztachelska M; Pilaszewicz-Puza A; Koda M; Bielawski T; Zbucka-Kretowska M; Pawelczyk A; Tomaszewski J; Li X; Huhtaniemi I; Wolczynski S; Rahman NA Fertil Steril; 2024 Aug; 122(2):341-351. PubMed ID: 38431184 [TBL] [Abstract][Full Text] [Related]
6. Progesterone is essential for maintenance and growth of uterine leiomyoma. Ishikawa H; Ishi K; Serna VA; Kakazu R; Bulun SE; Kurita T Endocrinology; 2010 Jun; 151(6):2433-42. PubMed ID: 20375184 [TBL] [Abstract][Full Text] [Related]
7. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Kim JJ; Sefton EC Mol Cell Endocrinol; 2012 Jul; 358(2):223-31. PubMed ID: 21672608 [TBL] [Abstract][Full Text] [Related]
8. [Estrogens and leiomyoma of the uterus]. Murakami T Nihon Rinsho; 2006 Apr; 64 Suppl 4():364-9. PubMed ID: 16689335 [No Abstract] [Full Text] [Related]
9. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Donnez J; Donnez O; Dolmans MM Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868 [TBL] [Abstract][Full Text] [Related]
10. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256 [TBL] [Abstract][Full Text] [Related]
11. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology]. Brazert M; Korman MP; Pawelczyk LA Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519 [TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma. Ohara N Clin Exp Obstet Gynecol; 2005; 32(1):9-11. PubMed ID: 15864926 [TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Islam MS; Ciavattini A; Petraglia F; Castellucci M; Ciarmela P Hum Reprod Update; 2018 Jan; 24(1):59-85. PubMed ID: 29186429 [TBL] [Abstract][Full Text] [Related]
18. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797 [TBL] [Abstract][Full Text] [Related]
19. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972 [TBL] [Abstract][Full Text] [Related]
20. Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures. Severino MF; Murray MJ; Brandon DD; Clinton GM; Burry KA; Novy MJ Mol Hum Reprod; 1996 Nov; 2(11):823-8. PubMed ID: 9237221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]